Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIBP-03 + cetuximab in recurrent/metastatic head and neck squamous cell carcinoma
NCT06194656Phase 2Recruiting
- Sponsor
- Shanghai Institute of Biological Products
- Start
- Sep 2024
- Primary completion
- Jul 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of SIBP-03 in head and neck squamous cell carcinoma (HNSCC), sponsored by Shanghai Institute of Biological Products. Started Sep 2024; status: recruiting.
02
Drugs
SIBP-03
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06194656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06194656.